Prostate-Specific Antigen Bounce Following Stereotactic Body Radiation Therapy for Prostate Cancer
Open Access
- 1 January 2014
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
Abstract
Introduction: Prostate-specific antigen (PSA) bounce after brachytherapy has been well-documented. This phenomenon has also been identified in patients undergoing stereotactic body radiation therapy (SBRT). While the parameters that predict PSA bounce have been extensively studied in prostate brachytherapy patients, this study is the first to analyze the clinical and pathologic predictors of PSA bounce in prostate SBRT patients. Materials and Methods: Our institution has maintained a prospective database of patients undergoing SBRT for prostate cancer since 2006. Our study population includes patients between May 2006 and November 2011 who have at least 18 months of follow-up. All patients were treated using the CyberKnife treatment system. The prescription dose was 3500-3625cGy in 5 fractions.Results: 120 patients were included in our study. Median PSA follow-up was 24 months (range 18-78 months). 34 (28%) patients had a PSA bounce. The median time to PSA bounce was 9 months, and the median bounce size was 0.50ng/mL. On univariate analysis, only younger age (p = .011) was shown to be associated with an increased incidence of PSA bounce. Other patient factors, including race, prostate size, prior treatment by hormones, and family history of prostate cancer, did not predict PSA bounces. None of the tumor characteristics studied, including Gleason score, pre-treatment PSA, T-stage, or risk classification by NCCN guidelines, was associated with increased incidence of PSA bounces. Younger age was the only statistically significant predictor of PSA bounce on multivariate analysis (OR = 0.937, p = 0.009).Conclusion: PSA bounce, which has been reported after prostate brachytherapy, is also seen in a significant percentage of patients after CyberKnife SBRT. Close observation rather than biopsy can be considered for these patients. Younger age was the only factor that predicted PSA bounce.Keywords
This publication has 17 references indexed in Scilit:
- Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 yearsRadiation Oncology, 2013
- Stereotactic Body Radiation Therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experienceRadiation Oncology, 2013
- Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- Hypofractionated stereotactic body radiotherapy in low‐risk prostate adenocarcinomaCancer, 2011
- Prostate-specific Antigen Bounce After Prostate Brachytherapy: Review of a Confusing PhenomenonUrology, 2009
- Stereotactic Body Radiotherapy for Localized Prostate Cancer: Interim Results of a Prospective Phase II Clinical TrialInternational Journal of Radiation Oncology*Biology*Physics, 2009
- Analysis of prostate-specific antigen bounce after I125 permanent seed implant for localised prostate cancerRadiotherapy and Oncology, 2008
- PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling timeInternational Journal of Radiation Oncology*Biology*Physics, 2005
- Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implicationsInternational Journal of Radiation Oncology*Biology*Physics, 2003
- Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer.2000